Translational pharmacokinetics: Current issues with newer antidepressants

Depression and Anxiety

Volumn 8, Issue SUPPL. 1, 1998, Pages 64-70

  DeVane, C Lindsay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cytochrome P450; Drug interactions; Fluoxetine; Selective serotonin reuptake inhibitors; Translational pharmacokinetics

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; STEREOISOMERISM;

ANTIDEPRESSIVE AGENTS; HUMANS;

EID: 0031786077     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1998)8:1+<64::AID-DA10>3.0.CO;2-S     Document Type: Article

References (24)

1. Beasley CM Jr, Bosomworth JC, Wernicke JF (1990) Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 26:18-24.
2. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 45:1211-1214.
3. Brown S-L, van Praag HM (1991) The Role of Serotonin in Psychiatric Disorders. New York: Brunner Mazel.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br J Clin Pharmacol 34:262-265.
5. Dawling S, Lynn K, Rosser R, Braithwaite R (1982) Nortriptyline metabolism in chronic renal failure: Metabolite elimination. Clin Pharmacol Ther 32:322-329.
6. DeVane CL (1997a) Principles of Pharmacokinetics and Pharmacodynamics. In Schatzberg AF, Nemeroff CB (eds): American Psychiatric Press Textbook of Psychopharmacology, 2nd Edition (in press).
7. DeVane CL (1997b) Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Cell Mol Neurobiol (in press).
8. DeVane CL, Laizure SC, Cameron DF (1986) The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs. Psychopharmacology 89:404-408.
9. Fava M, Rosenbaum JR, Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K (1992) High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Aff Dis 25:229-234.
10. Gram LF, Overo KF (1972) Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1:463-465.
11. Keck PE Jr, McElroy SL (1992) Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 53:127-129.
12. Kelly MW, Perry PJ, Holstad SG, Garvey MJ (1989) Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monitor 11:163-170.
13. Martensson B, Nyberg S, Toresson G, Brodtn E, Bertilsson L (1989) Fluoxetine treatment of depression. Acta Psychiatrica Scand 79:586-596.
14. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D (1990) Plasma level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 13: S71-S73.
15. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307.
16. Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
17. Norman RT, Gupta RK, Burrows GD, Parker G, Judd FK (1993) Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 8:25-29.
18. Price Evans DA (1995) Genetic Factors in Drug Therapy Clinical and Molecular Pharmacogenetics. London: Cambridge University Press.
19. Rowland M, Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553-567.
20. Sandler M, Coopen A, Hamett S (1991) 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. London: Oxford Medical Publications.
21. Skjelbo E, Brøsen K (1992) Inhibitors of imipramine metabolism by human liver microsoines. Br J Clin Pharmacol 34:256-261.
22. Tyrer SP, Marshall EF, Griffiths HW (1990) The relationship between response to fluoxetine, plasma drug levels, imipramine biding to platelet membranes and whole blood 5-HT. Prog Neuropsychopharmacol Biol Psychiat 14:797-805.
23. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15: 125-131.